The tumor suppressor protein p53, mutated in half of all human cancers, is a transcription factor regulated by several post-translational modifications, including phosphorylation, ubiquitylation, acetylation and methylation 1,2 . Depending on the site and extent of lysine methylation, p53 transcriptional activity is activated or inhibited. Monomethylation of Lys372 or dimethylation of Lys370 promotes p53-activated transcription, whereas monomethylation of Lys370 or Lys382 suppresses p53-mediated transcription [3] [4] [5] [6] . Dimethylation of Lys382 has been implicated in the recruitment of p53 to sites of DNA damage 6, 7 .
a r t i c l e s
The tumor suppressor protein p53, mutated in half of all human cancers, is a transcription factor regulated by several post-translational modifications, including phosphorylation, ubiquitylation, acetylation and methylation 1, 2 . Depending on the site and extent of lysine methylation, p53 transcriptional activity is activated or inhibited. Monomethylation of Lys372 or dimethylation of Lys370 promotes p53-activated transcription, whereas monomethylation of Lys370 or Lys382 suppresses p53-mediated transcription [3] [4] [5] [6] . Dimethylation of Lys382 has been implicated in the recruitment of p53 to sites of DNA damage 6, 7 .
How lysine methylation affects p53 function is poorly understood 8 . The best characterized effector for p53 methylation is 53BP1, a protein involved in cell-cycle checkpoint signaling and DNA repair. In 53BP1, tandem BRCA1 C terminus (BRCT) domains associate with the DNA-binding core domain of p53 (refs. 9,10) and its tandem Tudor domains recognize p53 dimethylated at Lys370 (p53K370me2) or Lys382 (p53K382me2) 4, 6, 7, 11 . Previously, we showed that 53BP1 tandem Tudor domains bind histone H4 dimethylated at Lys20 (H4K20me2) 12, 13 and identified a Tudor domain in human PHF20 (plant homeodomain finger-containing protein 20, also known as glioma-expressed antigen 2, GLEA2) as another H4K20me2 binder 12 .
PHF20 was initially described as an immunogenic antigen that elicits a strong antibody response in glioblastoma and adenocarcinoma patients [14] [15] [16] . Later, it was shown that PHF20 can transcriptionally activate p53 and be downregulated through phosphorylation by the Akt kinase 17 . PHF20 was also identified as a component of the 'male absent on the first' (MOF) lysine acetyltransferase [18] [19] [20] [21] [22] , which together with O-linked β-N-acetylglucosamine transferase, isoform 1 (OGT1) form the nonspecific lethal (NSL) complex 20, 22 . In the context of the NSL complex, MOF lysine acetyltransferase acetylates Lys120 in the DNA-binding domain of p53 when DNA damage occurs 21 , promoting p53-dependent transcription of pro-apoptotic genes without altering transcription of cell-cycle genes 23 . OGT1, in contrast, modifies p53 at Ser149, inducing p53 stabilization by preventing ubiquitin-dependent proteolysis 24 . The NSL complex, through MOF lysine acetyltransferase, acetylates histone H4 at Lys5, Lys8 and Lys16 (ref. 22) . Recent studies showed that Phf20-null mice die shortly after birth and that loss of PHF20 results in reduced expression of genes whose promoters are marked with high levels of H4K16ac, thus directly implicating PHF20 in transcriptional regulation 25 .
Here we set out to probe the function of human PHF20. We demonstrate that PHF20 specifically binds K370me2-or K382me2-containing p53 peptides in vitro. We characterize these interactions in detail using protein domain arrays, X-ray crystallography, NMR spectroscopy, calorimetry and cell assays, and show that one of the two Tudor domains in PHF20 contributes to the interaction with p53. A homodimeric form of this Tudor domain can bind doubly dimethylated p53 (p53K370me2K382me2), greatly strengthening the PHF20-p53 interaction in vitro. Functionally, we show that the PHF20-p53 association diminishes p53 ubiquitylation. Therefore, PHF20 emerges as a regulator of p53. PHF20 has the unique property of being a p53-specific transcription factor that also stabilizes p53 through direct interaction in a methylation-dependent manner.
RESULTS

Interaction of PHF20 with p53 in vitro and in cells
To probe the function of human PHF20, we conducted experiments in vitro and in cells (Fig. 1) . Based on its amino acid sequence, PHF20 is predicted to contain several domains including two Tudor domains, a plant homeodomain (PHD) finger and putative DNA-binding domains AT hook and C 2 H 2 -type zinc finger (Fig. 1a) . In an initial systematic screen using an array of more than 120 protein domains probed with methylated peptides, we identified PHF20 as a binder of methylated p53 (data not shown). Of the four known methylated forms of p53, p53K370me2 and p53K382me2 exhibited the strongest interaction with PHF20 (Supplementary Fig. 1 ). We used a condensed protein domain array including the two Tudor domains of PHF20 and homolog PHF20-like 1 (PHF20L1), with 53BP1 tandem Tudor domains serving as a positive control, to gauge binding of these domains to p53 peptides methylated to different degrees at Lys370 or Lys382 (Fig. 1b) . The results indicated that the second Tudor domain of PHF20 (PHF20 Tudor2) alone or in combination with the first Tudor domain (PHF20 Tudor1-2) interacted most strongly with p53K370me2 and p53K382me2 peptides, whereas the first Tudor domain alone (PHF20 Tudor1) exhibited no interaction (Fig. 1b) . These data suggest that the Tudor domains of PHF20 are independent modules. In agreement with these data, the 1 H-15 N heteronuclear single quantum coherence (HSQC) NMR spectra of the individual Tudor domains (PHF20 Tudor1 and PHF20 Tudor2) did not change when the other Tudor domain was also present (PHF20 Tudor1-2) (Fig. 2a) . We thus conclude that PHF20 Tudor2 can function alone in contrast to 53BP1 or JMJD2A, which both use double Tudor domains to bind methylated targets 13, 26, 27 .
To evaluate the biological relevance of the PHF20-p53 interaction, we tested whether the two proteins could form a complex in vivo using co-immunoprecipitation (co-IP) assays. Before this, we probed the cellular localization of EGFP-tagged full-length PHF20 and PHF20 Tudor1-2 constructs and found that both proteins were nuclear (Fig. 1c) . We observed, however, that EGFP-PHF20 Tudor1-2 was also present in the nucleoli, something not seen with the full-length protein (Fig. 1c) . We co-immunoprecipitated EGFP-p53 and Flag-PHF20 from lysates of human embryonic kidney (HEK 293) cells expressing these proteins using an anti-Flag antibody or an anti-p53 antibody (Fig. 1d) , revealing an interaction between PHF20 and p53. Similarly, endogenous p53 immunoprecipitated with EGFP-PHF20 Tudor1-2 using an anti-GFP antibody (Fig. 1d) . We also found that endogenous full-length PHF20 interacted with endogenous p53 in cell lines U87 (glioblastoma) and MCF7 (breast cancer), which both express wild-type p53 (Fig. 1e) .
PHF20 homodimerizes via its second Tudor domain
Although the first Tudor domain of PHF20 is monomeric, the second Tudor domain forms a stable homodimer cross-linked by two disulfide bonds. Dimerization was evident from the increased retention time in size exclusion chromatography and sharpening of all signals in the 1 H-15 N HSQC spectrum of PHF20 Tudor2 after we added DTT or when we mutated Cys96 and Cys100 to serines ( Supplementary  Fig. 2a) . We confirmed the dimeric state by mass spectrometry analysis. Conversion of dimeric PHF20 Tudor2 to a monomeric species (mPHF20 Tudor2) by mutating Cys96 and Cys100 did not affect the structure of the domain. In the presence of 20 mM DTT, the majority of signals in the 1 H-15 N HSQC spectra of mPHF20 Tudor2 and wild-type PHF20 Tudor2 were superimposable (Supplementary Fig. 2b ). There were small differences in chemical shifts that we had expected from the disruption of the dimer interface ( Supplementary Fig. 2b,c) .
We determined the crystal structures of PHF20 Tudor1 and PHF20 Tudor2 to resolutions of 1.93 Å and 2.0 Å, respectively ( Fig. 2 and EGFP-p53; co-immunoprecipitated protein (Flag-PHF20 or EGFP-p53) was detected by western blot (WB) using the respective antibody. In HEK 293 cells transfected with a plasmid encoding EGFP-PHF20 Tudor1-2 or EGFP, EGFP-PHF20 Tudor1-2 was immunoprecipitated using an anti-GFP antibody, and endogenous p53 was detected by WB using an anti-p53 antibody. (e) Immunoprecipitation of endogenous PHF20 from U87 and MCF7 cells lysates using an anti-PHF20 antibody. Co-IP of p53 was detected by WB using an anti-p53 antibody. npg a r t i c l e s subunit A forming disulfide bonds with Cys100 and Cys96 of subunit B, respectively (Fig. 2b) . The lack of signal duplication in the 1 H-15 N HSQC spectrum of PHF20 Tudor2 dimer indicates that only one of two possible sets of disulfide bonds is formed, consistent with a specific dimer. Each subunit consists of five β-strands and one 3 10 -helix, and has a β-barrel fold characteristic of the Tudor domain. The dimer interface is made up of nine residues (Cys96, Trp97, Ser98, Asp99, Cys100, Phe102, Val108, Lys109 and His112) and buries a surface area of 670 Å 2 . Five residues (Trp97, Tyr103, Phe120, Val124 and Asp122) form an enclosure reminiscent of the dimethyllysine binding cage of 53BP1 (ref. 13) , with the possibility of van der Waals and cation π contacts between aromatic rings and a methylammonium group (Fig. 2c) . As is the case for the tandem Tudor domains in 53BP1, the side-chain carboxylate of Asp122 in PHF20 Tudor2 faces into the hydrophobic pocket, an orientation that would favor formation of a hydrogen bond with the amino proton of a dimethylated lysine. Using NMR chemical shift perturbation, we found that both the dimeric and monomeric forms of PHF20 Tudor2 bind p53K370me2 or p53K382me2 peptides. Individual affinities were weak but large affinity enhancement resulted upon simultaneous recognition of p53K370me2 and p53K382me2 as explained below. The structure of PHF20 Tudor1 revealed a characteristic Tudor fold similar to that of PHF20 Tudor2 (Fig. 2d) . PHF20 Tudor1 retained three aromatic side chains (Tyr29, Phe47 and Tyr54) and an aspartate (Asp23) that form a cage, but this cavity was blocked by a tryptophan (Trp50), making it unlikely that this Tudor domain would bind a methylated lysine (Fig. 2d) . In contrast to the case in PHF20 Tudor1, the first Tudor domain of PHF20L1 specifically bound a p53K382me1 peptide (Fig. 1b) . The structure of PHF20L1 Tudor1 revealed a canonical methyllysine binding cage (data not shown).
PHF20 Tudor2 recognition of p53K370me2 and p53K382me2
To verify that the cage identified in PHF20 Tudor2 can accommodate the dimethylated Lys370 or Lys382, we prepared four chimeric proteins by linking p53 sequences to the N terminus (N-terminally linked constructs) or C terminus (C-terminally linked constructs) of mPHF20 Tudor2 and chemically converting Cys370 or Cys382 of linked p53 into dimethyllysine analogs K C 370me2 or K C 382me2, respectively. Provided that the stereochemical orientation of p53 and PHF20 in the fused constructs did not preclude binding, we expected that tethering the partner molecules would enhance their strength of association to a level where structure determination might be possible.
We compared the 1 H-15 N HSQC spectra recorded for the conversion of Cys370 or Cys382 to K C 370me2 or K C 382me2 in the four chimeric proteins to the titration spectra of mPHF20 Tudor2 with p53K C 370me2 or p53K C 382me2 peptides (Fig. 3) . The 1 H-15 N HSQC spectra of mPHF20 Tudor2 in the chimeric proteins before dimethylation are virtually identical to those of mPHF20 Tudor2 before any peptide addition (data not shown). After dimethylation, we observed major changes in chemical shifts for the two C-terminally linked constructs PHF20 Tudor2-p53K C 370me2 and PHF20 Tudor2-p53K C 382me2 (Fig. 3c,d ) and smaller changes for the N-terminally linked constructs p53K C 370me2-PHF20 Tudor2 and p53K C 382me2-PHF20 Tudor2 (Fig. 3e,f) . This indicates that an interaction between the Tudor domain and the linked p53 fragment only occurs after formation of K C 370me2 or K C 382me2 and that the relative orientation of the Tudor domain and p53 peptide enforced by the npg a r t i c l e s C-terminal linkage is favored. The extent of chemical shift changes in the fusion proteins for the C-and N-terminally linked constructs is equivalent to adding more than 80-fold and about fourfold excess of methylated p53 peptides to mPHF20 Tudor2, respectively. The directions of perturbations upon dimethylation of the C-terminally linked complexes are similar to those in the titrations of mPHF20 Tudor with p53K C 370me2 or p53K C 382me2 peptides (Fig. 3a,b) , consistent with similar modes of interactions.
To test the specificity for dimethylation over trimethylation, we collected 1 H-15 N HSQC spectra for the C-terminally linked PHF20 Tudor-p53C370 chimera before and after trimethylation ( Supplementary Fig. 3 ). The chemical shift perturbations were extremely small compared to those seen with the dimethylation of PHF20 Tudor2-p53C370 or PHF20 Tudor2-p53C382 (Fig. 3) , demonstrating that PHF20 Tudor2 did not recognize the trimethylated forms of p53. PHF20 Tudor2 did, however, recognize p53 monomethylated at Lys370 or at Lys382 but with lower affinity than dimethylated p53 (see below and Fig. 3g,h ).
NMR structure of mPHF20 Tudor2 fused to p53K C 370me2
We determined the NMR structure of the high-affinity linked complex PHF20 Tudor2-p53K C 370me2 ( Fig. 3i and Table 2 ). The NMR and crystal structures superimpose well with an r.m.s. deviation of 1.25 Å for the backbone atoms N, C α and C′ of PHF20 residues Asn90 to Phe136. In PHF20 Tudor2-p53K C 370me2, the p53 sequence was rigid to a certain degree, as shown by the steady-state { 1 H}-15 N heteronuclear nuclear Overhauser enhancement (NOE) measurements (Supplementary Fig. 4 ). As expected, K C 370me2 was surrounded by methyllysine binding cage residues Trp97, Tyr103, Phe120, Val124 and Asp122 of PHF20 (Fig. 3i) . The carboxylate group of Asp122 contributed to favorable coulombic interaction with the dimethylammonium ion of K C 370me2 and was most likely involved 15 N HSQC spectra of PHF20 Tudor2-p53C370 and PHF20 Tudor2-p53K C 370me2 (c), PHF20 Tudor2-p53C382 and PHF20 Tudor2-p53K C 382me2 (d), p53C370-PHF20 Tudor2 and p53K C 370me2-PHF20 Tudor2 (e), and p53C382-PHF20 Tudor2 and p53K C 382me2-PHF20 Tudor2 (f). (g,h) Overlaid 1 H-15 N HSQC spectra of PHF20 Tudor2-p53K370 and PHF20 Tudor2-p53K370me1 monomethylated by SMYD2 (g) and of PHF20 Tudor2-p53K382 and PHF20 Tudor2-p53K382me1 monomethylated by SET8 (h). (i) Superposition of the 20 lowest energy structures of PHF20 Tudor2-p53K C 370me2 with N, C α and C′ backbone atoms in line representation (left) and ribbon representation of the lowest energy structure (middle). Residues 83-147 of PHF20 and 363-374 of p53 are colored gray and blue, respectively; side chains of dimethyllysine binding cage residues are shown in orange. Surface electrostatic potential of PHF20 Tudor2 in the PHF20 Tudor2-p53K C 370me2 linked complex and p53 segment in stick representation (right). npg a r t i c l e s in a hydrogen bond with the amino proton of K C 370me2, although this was not apparent in the NMR ensemble owing to a lack of NOE measurements between Asp122 and K C 370me2. Other residues of PHF20 Tudor2 (Arg101, Pro104, Tyr121 and Asp99) and p53 (His368, Leu369, Lys372 and Lys373) were involved in the interaction. Arg101 contacts His368; Pro104 and Tyr121 are part of a hydrophobic network with Leu369; Asp99 is close to Lys372, and Lys373 and could interact via charge-charge interactions. The area around the hydrophobic cage of mPHF20 Tudor2 is predominantly negatively charged, complementing the positively charged lysines and dimethyllysine of p53 (Fig. 3i) . The contacts observed between PHF20 and p53 in the structure of PHF20 Tudor2-p53K C 370me2 are in agreement with the chemical shift perturbations resulting from dimethylation of PHF20 Tudor2-p53C370 or PHF20 Tudor2-p53C382, or from the titrations of PHF20 Tudor2 or mPHF20 Tudor2 with p53K C 370me2 or p53K C 382me2 peptides (Fig. 3a-f) . Mutating Trp97 and Tyr103 in the methyllysine binding cage of PHF20 Tudor2-p53K C 370me2 to alanines prevented complex formation while preserving the structure of PHF20 Tudor2 (data not shown). The W97A and Y103A mutations markedly decreased the interaction of PHF20 with p53 in the context of full-length proteins in cells as indicated below.
PHF20-based sensors of lysine methylation
The tight association of methylated p53 with PHF20 Tudor2 in the linked constructs makes these chimeric proteins potentially useful as sensors or reporters of lysine methylation. Indeed, treatment of PHF20 Tudor2-p53K370 and PHF20 Tudor2-p53K382 with the human lysine methyltransferases SMYD2 (ref . 28) and SET8 (refs. 29,30) , respectively, in the presence of methyl donor S-adenosyl methionine led to changes in PHF20 chemical shifts, demonstrating methylation of p53K370 and p53K382 (Fig. 3g,h) . The changes were less pronounced than those observed after chemical dimethylation of the linked constructs (Fig. 3c,d) , consistent with monomethylation. SMYD2 and SET8 have previously been reported to specifically monomethylate p53 at Lys370 and Lys382, respectively 3, 5 . Therefore, this NMR spectroscopy-based approach provides information not only on the site but also on the state of lysine methylation. Although NMR chemical shift perturbation procedures have been developed to investigate protein phosphorylation and acetylation in vitro and in cell extracts or even in living cells [31] [32] [33] , to our knowledge no procedure exists for detecting lysine methylation. This is because, unlike phosphorylation or acetylation, methylation does not perturb the backbone NMR signals of the modified residue. In the linked constructs, PHF20 has the role of a signal amplifier, giving rise to large changes in chemical shifts upon methylation of p53.
This simple methodology could be used to probe methylation or demethylation activity in cell extracts or in vivo after injection of the sensor constructs in living cells. Possible applications are the validation of predicted lysine methyltransferases or demethylases and the screening of small-compound inhibitors of these enzymes.
Dual recognition of doubly dimethylated p53 by PHF20 Tudor2
We used NMR spectroscopy to investigate whether the Tudor homodimer could simultaneously recognize the methylation sites Lys370 and Lys382 in p53. The titrations of 15 N-labeled PHF20 Tudor2 with nonlabeled p53 peptides (amino acids 363-389) harboring single dimethylation (p53K C 370me2 or p53K C 382me2) or double dimethylation (p53K C 370me2K C 382me2) led to perturbation of the same signals in the 1 H-15 N HSQC spectrum of PHF20 Tudor2, demonstrating a conserved binding interface for the three peptides (data not shown). Although the exchange between free and PHF20 Tudor2-bound peptide was fast on the time scale of NMR chemical shifts when only Lys370 or Lys382 is dimethylated, the exchange was intermediate when these two sites are both dimethylated (Fig. 4a) . This suggests enhanced avidity through multivalent recognition of K C 370me2 and K C 382me2 by PHF20 Tudor2. These results are consistent with the complementary titrations of p53 peptides, specifically 13 C-labeled at the methyl groups of K C 370me2 and K C 382me2, with unlabeled PHF20 Tudor2 dimer (Fig. 4b) . There was no marked shift in the 13 C methyl signals of all three p53 peptides but there was progressive decrease in signal intensities during the titration, indicative of intermediate exchange on the time scale of NMR chemical shifts (Fig. 4b) . Signal disappearance was fastest when the two sites were both dimethylated compared to when either site was dimethylated in an equimolar mixture of p53K370me0K C 382me2 and p53K C 370me2K382me0, in agreement with a gain in apparent affinity brought about by the dual recognition mode. Strongly supporting this interpretation, the decrease in 1 H-13 C me2 NMR signal intensities was the same when p53K C 370me2K C 382me2 or the equimolar mixture p53K370me0K C 382me2 and p53K C 370me2K382me0 peptides were used for titrations with mPHF20 Tudor2 (Fig. 4b) .
As an additional control, we also examined possible double recognition of p53K C 372me2K C 382me2 by the PHF20 Tudor2 dimer. The distance separating Lys372 from Lys382 is in principle long enough to allow the simultaneous recognition of K372me2 and K382me2 by the two aromatic cages of PHF20 Tudor2 dimer. We know that a p53K372me2 peptide can interact with PHF20 Tudor2 but exhibits markedly weaker binding compared to p53K370me2 or p53K382me2 (Supplementary Fig. 1 ). As shown by the NMR titration of PHF20 Tudor2 dimer with p53K C 372me2K C 382me2, we observed no affinity enhancement (Supplementary Fig. 5a ). By quantifying the gain in affinity owing to dual recognition, we determined an apparent K d of 99.0 ± 15.7 µM using isothermal titration calorimetry (ITC) for the interaction of PHF20 Tudor2 dimer with the p53K C 370me2K C 382me2 peptide. The stoichiometry parameter (n) is close to unity (n = 0.93 ± 0.29 (± s.d.)), indicating that one dimeric protein binds one doubly dimethylated peptide. It is important to note that the strength of interaction is underestimated because a methyllysine analog leads to a K d incrase by ~100-200% compared to that for a real methyllysine 34 (unpublished data). Therefore, the true K d achieved from the double recognition mode of PHF20 Tudor2 is expected to be lower than 50 µM, which is the same affinity range as for other methylated peptide-binding domains such as the tandem Tudor domains of 53BP1. Under identical conditions, we detected no marked ITC signal when we titrated mPHF20 Tudor2 with p53K C 370me2K C 382me2 (Fig. 4c) . These results from ITC experiments are in agreement with those from NMR spectroscopy, where we obtained high K d values of 4.6 ± 0.6 mM and 3.5 ± 0.5 mM for the binding of the p53K C 370me2K382me0 and p53K370me0K C 382me2 peptides to mPHF20 Tudor2, respectively (Supplementary Fig. 5b ). The gain in affinity from dual recognition by PHF20 Tudor2 dimer was ~50-fold.
We could not crystallize the PHF20 Tudor2-53K C 370me2K C 382me2 complex. However, we generated a model of the complex in docking calculations combining information from the NMR spectroscopy structure of the PHF20 Tudor2-p53K C 370me2 complex, the crystal structure of dimeric PHF20 Tudor2 and the NMR spectroscopy-based titration of PHF20 Tudor2 with a p53K C 370me2K C 382me2 peptide. Figure 4 Evidence for dual recognition of p53K370me2K382me2 by PHF20 Tudor2 dimer. (a) Location of Trp97 and its indole NH group in the dimethyllysine binding site of PHF20 Tudor2, taken from the NMR structure of PHF20 Tudor2-p53K C 370me2 linked complex (left). Changes in the signal of Trp97 indole NH spin pair in the 1 H-15 N HSQC spectrum of PHF20 Tudor2 dimer upon titration with, from top to bottom, p53K C 370me2K382me0, p53K370me0K C 382me2 and p53K C 370me2K C 382me2 peptides (right). (b) Changes in 1 H- 13 C HSQC signal intensity of K C me2 in p53 upon titration of p53K C 370me2K C 382me2 and an equimolar mixture of p53K C 370me2K382me0 and p53K370me0K C 382me2 with dimeric PHF20 Tudor2, represented by red and blue lines, respectively; similar titrations as above but with monomeric mPHF20 Tudor2 are shown in orange and black lines (left). 1 H- 13 C HSQC correlation signals used to measure the K C me2 intensities in p53 (right). (c) ITC analysis of the p53K C 370me2K C 382me2 peptide (amino acids 363-389) with PHF20 Tudor2 dimer and mPHF20 Tudor2. The p53 peptide (4 mM) was injected in the calorimeter cell containing initial concentrations of 50 µM and 100 µM of PHF20 Tudor2 dimer (red and black curves, respectively), and 100 µM and 200 µM of mPHF20 Tudor2 (blue and orange curves, respectively). Apparent K d , stoichiometry (n) and s.d. are indicated. The top x axis is for the red and blue curves. The bottom x axis is for the black and orange curves. (d) Model of PHF20 Tudor2 in complex with p53K C 370me2K C 382me2 obtained from docking calculations using the crystal structure of PHF20 Tudor2. 
r t i c l e s
From the model, the doubly dimethylated p53 peptide fit nicely in a groove formed between the two Tudor domains in the homodimer opposite the two disulfide bonds (Fig. 4d) . The ~25 Å distance separating the two methylated sites, p53K C 370me2 and p53K C 382me2, is optimal for their simultaneous recognition by the two binding cages of PHF20 Tudor2. Therefore, specificity and tighter binding are determined by an optimal dual recognition of the two methylated sites in p53.
PHF20 stabilizes p53 by inhibiting p53 ubiquitylation
To probe the importance of p53 methylation for the PHF20-p53 interaction in vivo, we checked whether mutations that affect the interaction of PHF20 Tudor2 with p53K370me2 or p53K382me2 peptides but preserve the Tudor domain fold would alter the affinity of PHF20 for p53 in the context of full-length proteins. The W97A or Y103A mutations in the methyllysine binding cage of PHF20 both markedly diminished the affinity of PHF20 for p53 in cells (Fig. 5a) . To begin to address the functional importance of the PHF20-p53 complex, we then checked whether PHF20 would affect the stability of p53. Ubiquitylation of p53 by the ubiquitin ligase Mdm2 has an essential regulatory role in that it controls p53 nuclear export and degradation 35 .
The majority of p53 sites ubiquitylated by Mdm2 are located at its C terminus (for example, Lys370, Lys372, Lys373, Lys381, Lys382 and Lys386) 36 , precisely where PHF20 binds p53. Furthermore, both the N-and the C-terminal regions of p53 have been implicated in direct contacts with Mdm2 (ref. 37) . Therefore, the direct PHF20-p53 interaction would likely prevent or diminish ubiquitylation. Consistent with this possibility, a pulse-chase assay showed that the degradation of p53 was decreased in HCT 116 cells transfected with plasmid encoding PHF20 (Fig. 5b) . Furthermore, Mdm2-mediated a r t i c l e s ubiquitylation of p53 was reduced in the presence of PHF20 (Fig. 5c) . This protection by PHF20 was diminished when the methyllysine binding cage of PHF20 was mutated to prevent interaction with p53K370me2 and p53K382me2 ( Supplementary Fig. 6a,b) . It is therefore likely that dimethylation of p53 at Lys370 or Lys382 or at both sites acts as a molecular switch that diminishes p53 ubiquitylation by triggering a direct interaction with PHF20 that blocks Mdm2 from accessing p53.
PHF20 contributes to p53 upregulation after DNA damage
To determine whether PHF20 might regulate stress-induced p53 expression, we knocked down PHF20 using small interfering RNA (siRNA) before challenging HCT 116 cells with the genotoxic agents doxorubicin or etoposide. Knockdown of PHF20 substantially reduced the p53 levels induced by doxorubicin or etoposide in wild-type TP53 but not in TP53-null HCT 116 cells (Fig. 6a,b) . We verified that the two genotoxic agents also induced phosphorylation of p53 at Ser15, a key phosphorylation target during p53 activation (Fig. 6b) . Consistent with the reduced expression of p53, the levels of p21 and Bax proteins were also decreased (Fig. 6a) . Moreover, a chromatin immunoprecipitation (ChIP) assay showed that binding of p53 to the p21 promoter was considerably reduced by knockdown of PHF20 (Fig. 6c) . These results indicate that PHF20 contributes to the upregulation of p53 expression in response to genotoxic stress.
Ectopic expression of PHF20 activates p53
We checked whether ectopic expression of p53 in different cell lines would lead to phenotypic changes that are consistent with p53 activation. We prepared stable MCF7 Tet-off (wild-type TP53), HCT 116 (wild-type TP53) and HCT 116 TP53-null cell lines expressing Flagtagged PHF20 or PHF20 (Fig. 7a) . Then we evaluated cell growth, DNA synthesis, cell survival and cell-cycle progression using eight clonal cell lines for each transfectant. Cell growth was clearly inhibited by ectopic expression of PHF20 in cells expressing wild-type p53 (Fig. 7b) . Similarly, DNA synthesis was repressed by PHF20 as shown from reduced [ 3 H]thymidine incorporation when PHF20 was expressed (Fig. 7c) . Cell death by doxorubicin or etoposide was ~40% enhanced upon expression of PHF20 (Fig. 7d) . In cells synchronized with nocodazole treatment, induction of PHF20 led to delayed cell-cycle transitions from G1 to S and M to G1 phases ( Fig. 7e and Supplementary Fig. 6c,d) . We obtained similar results with stably transfected A2780S (wild-type TP53) and A2780CP (mutated TP53) cell lines (data not shown). Therefore, we conclude that PHF20 regulates cell proliferation and survival, as well as G1-S and G2-M cellcycle checkpoints, which are hallmarks of p53 activation.
DISCUSSION
In this study we showed that PHF20 forms a complex with p53 in human cells and that this interaction is dependent on a functional Tudor domain that drives a methyllysine-dependent protein-protein interaction. The second Tudor domain of PHF20 interacts specifically with p53 peptides monomethylated or dimethylated at Lys370 or Lys382. The dissociation constants for these interactions are in the millimolar range, which is not uncommon for isolated methyllysine or methylarginine recognition domains probed with peptides 34, 38, 39 . These domains often belong to modular proteins involved in combinatorial interactions giving rise to effective tight associations [40] [41] [42] . PHF20 is modular, harboring five recognizable domains, including two Tudor domains, a PHD finger as well as an AT hook and a C 2 H 2 -type zinc finger, which both are putative DNA-binding domains. Indeed, it was recently shown that PHF20 specifically binds DNA 17 .
PHF20 is a subunit of the NSL complex containing the enzymes MOF lysine acetyltransferase and OGT1 known to modify p53 (refs. 18-22) . It is therefore likely that in the cellular environment, PHF20 participates in simultaneous multiple interactions with other proteins or DNA. Combinatorial interactions may also occur owing to PHF20 dimerization. PHF20 Tudor2 forms a bis-disulfide cross-linked homodimer that participates in a divalent interaction with methylated p53 in vitro. We determined that substantial affinity with an apparent K d in the micromolar range, comparable to that of 53BP1 tandem Tudor domains, is achieved when p53 is dimethylated at two sites (Lys370 and Lys382), with each methyllysine being recognized by a different Tudor domain of the PHF20 Tudor2 homodimer. This finding provides a proof of principle of enhanced specificity and selectivity by double methyllysine recognition. Binding to two methylated lysines has also been shown for the lysine demethylase PHF8, which associates with H3K4me3 and H3K9me2 via a PHD finger and the catalytic jumonji domain, respectively 43 .
Although PHF20 Tudor2 and Tudor1-2 proteins purified from overexpression in Escherichia coli are dimeric, it is not known whether a PHF20 homodimer forms in the nucleus of eukaryotic cells. This is, however, plausible as there are nuclear proteins that dimerize via disulfide bonds. For example, the mammalian E2A transcription factor homodimer is regulated by formation of an intermolecular disulfide bond necessary for high-affinity DNA binding in vivo 44 . A pair of disulfide bonds like in PHF20 Tudor2 homodimer is expected to have a more negative overall redox potential than a single disulfide bond and therefore more resistance to reduction in cells. Dimerization via disulfide bonds also offers the possibility of redox control of the PHF20-methylated p53 complex. The observed coimmunoprecipitations of differently tagged full-length PHF20 from cellular extracts supports the possibility that PHF20 homodimerizes in cells (Supplementary Fig. 7) .
Our data strongly suggest that the interaction of PHF20 with p53K370me1/2 or p53K382me1/2 or both stabilizes p53 by preventing Mdm2-mediated ubiquitylation. The p53 ubiquitylation sites overlap with the binding area covered by PHF20 Tudor2, likely explaining the stabilization of p53 by PHF20. Previous studies have shown that dimethylation of p53 at Lys370 promotes p53-activated transcription but the mechanism for such activation is not known 4 . Protection of p53 from degradation by dimethylation of Lys370 may partly explain this finding. Furthermore, we showed that activation of p53 by PHF20 is enhanced in response to DNA damage. This may be due to the demonstrated increased p53 dimethylation at Lys382 with DNA damage 6, 7 .
The ubiquitylation of p53 by Mdm2 is regulated by the Akt kinase, which stimulates the translocation of Mdm2 from the cytoplasm to the nucleus, where it binds p53 and drives its degradation 45 . Akt also phosphorylates PHF20 at Ser291, leading to PHF20 translocation from the nucleus to the cytoplasm 17 . Therefore, the opposite directionality Akt-triggered Mdm2 and PHF20 translocations and antagonistic functions of Mmd2 and PHF20 synergistically contribute to p53 regulation.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Protein Data Bank: coordinates for the structures have been deposited with accession codes 3SD4 (PHF20 Tudor1), 3P8D (PHF20 Tudor2) and 2LDM (PHF20 Tudor2-p53K C 370me2). npg a r t i c l e s Biological Magnetic Resonance Bank: NMR chemical shifts of PHF20 Tudor2-p53K C 370me2 have been deposited with the accession code 17673. 500 µl solution of 0.3 N NaOH and 1% SDS for 30 min at 37 °C. Incorporated radioactivity was quantified by liquid scintillation counting.
RNA interference (RNAi).
RNAi duplexes were synthesized by Dharmacon. The cDNA-targeted region and the sequence of PHF20 siRNA duplexes were: AAGAGGAUGGAUCUUCUGAAU and AAAGCAUUGGAGGAGGAUAAU. RNAi duplexes were reconstituted to 20 µM in sterile RNase-free water. Transfection of siRNA for targeting of endogenous genes was performed using oligofectamine reagent (Invitrogen).
Flow cytometry and cell-cycle analysis. PHF20 plasmid-transfected MCF7 Tet-off cells were cultured in doxycycline-free medium for 12 h and then treated with 40 ng ml −1 nocodazole for 12 h to synchronize cells in M phase. Cells were washed and cultured in fresh medium without nocodazole for different durations. Cells were fixed in prechilled 70% ethanol for 2 h, washed with PBS, resuspended in propidium iodide (PI) staining solution (20 µg ml −1 PI in PBS, 0.1% Triton X-100 and 0.2 mg ml −1 DNase-free RNase A) for 15 min at 37 °C and then analyzed by flow cytometry. DNA content histograms and fluorescence-activated cell sorting data were analyzed using FlowJo.
In vivo ubiquitylation assay. H1299 cells were co-transfected with plasmids encoding wild-type HA-p53, Flag-PHF20, Myc-ubiquitin and Mdm2, and then treated with 50 µM of proteasome inhibitor MG132 (Sigma) for 2 h before collecting the cells. After two washes with ice-cold PBS, cells were lysed in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol and protease inhibitors. Cell lysates were immunoprecipitated with an anti-HA antibody and then blotted with an anti-Myc antibody. Ubiquitylation assays were also done in MCF7 cells in the context of endogeneous wild-type p53 (Supplementary Fig. 6b ).
